Back to Search Start Over

Seroprevalence of mumps in an epidemic period in Medellín, Colombia.

Authors :
Santacruz-Sanmartín E
Hincapié-Palacio D
Ospina MC
Perez-Toro O
Bernal-Restrepo LM
Buitrago-Giraldo S
Lenis-Ballesteros V
Díaz FJ
Source :
Vaccine [Vaccine] 2015 Oct 13; Vol. 33 (42), pp. 5606-5612. Date of Electronic Publication: 2015 Sep 10.
Publication Year :
2015

Abstract

Objective: We related seroprevalence and outbreaks data in order to identify factors that could explain the occurrence of outbreaks despite high vaccination coverage in Medellín Colombia.<br />Methods: Samples from a population seroprevalence data obtained in 2009 in a random survey were analyzed. IgG levels were determined for mumps using 2 commercial tests of 2119 individuals aged 6-64 years. A comparative analysis was undertaken using age-specific mumps seroprevalence data and information of 98 epidemiological investigations of mumps outbreaks reported in 2009.<br />Results: Overall, seroprevalence was 91.6% (95% CI=89.3-93.5%). The age-specific seronegativity was 20.3% and 20.6% in age groups 11-15 years and 16-20 years respectively. Individuals aged 6-20 years were the most affected during outbreaks. In individuals born in 2003, a year after the change in the booster schedule from 10 to 5 years, the proportion of unvaccinated individuals (14%) and those who received only one dose of MMR (45%) increased substantially. On average, 23.5 days elapsed between the onset of symptoms in secondary cases and the outbreak investigation.<br />Conclusion: Potential contributing factors for the occurrence of outbreaks of mumps were the relatively high prevalence of seronegativity among individuals aged 11-20 years, delays in investigation and control of outbreaks, and incomplete vaccination schedules.<br /> (Copyright © 2015 Elsevier Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1873-2518
Volume :
33
Issue :
42
Database :
MEDLINE
Journal :
Vaccine
Publication Type :
Academic Journal
Accession number :
26363380
Full Text :
https://doi.org/10.1016/j.vaccine.2015.08.088